Pharvaris (NASDAQ:PHVS - Get Free Report) shares saw unusually-strong trading volume on Wednesday . Approximately 71,000 shares changed hands during trading, an increase of 59% from the previous session's volume of 44,547 shares.The stock last traded at $15.00 and had previously closed at $14.83.
Analysts Set New Price Targets
Separately, JMP Securities upped their price target on shares of Pharvaris from $46.00 to $55.00 and gave the company a "market outperform" rating in a report on Friday, January 31st.
Read Our Latest Stock Report on Pharvaris
Pharvaris Stock Down 7.5 %
The stock has a market cap of $690.75 million, a P/E ratio of -4.72 and a beta of -2.84. The firm's 50 day simple moving average is $16.31 and its two-hundred day simple moving average is $18.70.
Pharvaris (NASDAQ:PHVS - Get Free Report) last announced its quarterly earnings data on Wednesday, April 9th. The company reported ($0.68) earnings per share for the quarter, beating analysts' consensus estimates of ($0.74) by $0.06. As a group, equities analysts predict that Pharvaris will post -2.71 EPS for the current year.
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Public Employees Retirement System of Ohio acquired a new stake in Pharvaris in the third quarter worth $57,000. JPMorgan Chase & Co. increased its holdings in shares of Pharvaris by 1,125.3% in the 4th quarter. JPMorgan Chase & Co. now owns 3,100 shares of the company's stock worth $59,000 after acquiring an additional 2,847 shares during the period. Cubist Systematic Strategies LLC bought a new stake in Pharvaris in the 4th quarter valued at about $64,000. Barclays PLC bought a new position in Pharvaris in the 3rd quarter worth about $106,000. Finally, KLP Kapitalforvaltning AS bought a new position in Pharvaris in the 4th quarter worth about $111,000.
Pharvaris Company Profile
(
Get Free Report)
Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.
Recommended Stories
Before you consider Pharvaris, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pharvaris wasn't on the list.
While Pharvaris currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
